[Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma]

Authors :: M, Zhang
P, Wu
Y L, Duan
L, Jin
J, Yang
S, Huang
Y, Liu
B, Hu
X W, Zhai
H S, Wang
Y, Fu
F, Li
X M, Yang
A S, Liu
S, Qin
X J, Yuan
Y S, Dong
W, Liu
J W, Zhou
L P, Zhang
Y P, Jia
J, Wang
L J, Qu
Y P, Dai
G T, Guan
L R, Sun
J, Jiang
R, Liu
R M, Jin
Z J, Wang
X G, Wang
B X, Zhang
K L, Chen
S Q, Zhuang
J, Zhang
C J, Zhou
Z F, Gao
M C, Zheng
Yonghong, Zhang
Source :: Zhonghua er ke za zhi = Chinese journal of pediatrics. 60(10)
Publication Year :: 2022

Subjects :: Male
Lymphoma, B-Cell
Adolescent
Prognosis
Burkitt Lymphoma
Disease-Free Survival
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols
Humans
Female
Child
Rituximab
Lactate Dehydrogenases
Retrospective Studies

Tools